<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1932">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136014</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI057</org_study_id>
    <nct_id>NCT05136014</nct_id>
  </id_info>
  <brief_title>Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model</brief_title>
  <acronym>OS-TUMOVASC</acronym>
  <official_title>Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is a major public health problem and remains the leading cause of cancer&#xD;
      mortality worldwide. Moreover, in France, it is the 3rd most common cancer in terms of&#xD;
      incidence. Its prognosis remains poor despite the emergence of new therapies, notably the&#xD;
      Epithelial Growth Factor Receptor (EGFR) specific tyrosine kinase inhibitors which can be&#xD;
      used in patients with adenocarcinoma presenting an activating mutation of EGFR.&#xD;
&#xD;
      In addition, a number of questions remain regarding the use of these molecules, including the&#xD;
      possibility of combining them with other therapies such as chemotherapy or radiotherapy. In&#xD;
      addition, the duration of treatment with tyrosine kinase inhibitors is a matter of debate,&#xD;
      mainly in localised forms (ADAURA trial). For this reason, we have proposed tests using TKIs&#xD;
      on an in vitro platform based on organoid formation from tumour biopsies of NSCLC patients.&#xD;
      This model will allow to test different molecules, in particular osimertinib which is a third&#xD;
      generation tyrosine kinase inhibitor. In this way, it will be possible to evaluate in vitro&#xD;
      responder patients within a timeframe compatible with the timeframe proposed by the INCA (4-6&#xD;
      weeks).&#xD;
&#xD;
      For non-responders, it will also be possible to screen them in vitro and seek the ideal&#xD;
      alternative therapy. This model therefore aims to develop personalised medicine in thoracic&#xD;
      oncology and could be used as a decision aid during multidisciplinary consultation meetings.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Actual">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Evaluation of the in vitro efficacy of osimertinib in a patient-derived organoid model alone or in combination</measure>
    <time_frame>from day 0 to day 30</time_frame>
    <description>Cell viability test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify non-responders to osimertinib in vitro</measure>
    <time_frame>from day 0 to day 30</time_frame>
    <description>Cell viability test</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Adenocarcinoma</condition>
  <condition>EGFR Activating Mutation</condition>
  <condition>KRAS Mutation-Related Tumors</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>General cohorte</arm_group_label>
    <description>patient with non-small cell lung cancer undergoing surgical resection in the thoracic surgery department of the Nancy CHRU</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of surgical waste</intervention_name>
    <description>collection of a fragment of healthy and tumorous lung tissue taken as part of the operating theatre procedure and normally destined to be destroyed</description>
    <arm_group_label>General cohorte</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with non small cell lung cancer of any stage undergoing surgical resection at the&#xD;
        Nancy University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18 years or older&#xD;
&#xD;
          -  patient affiliated to a social security scheme&#xD;
&#xD;
          -  having given their agreement to participate in the study&#xD;
&#xD;
          -  with non small cell lung cancer of any stage undergoing surgical resection at the&#xD;
             Nancy University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  HIV&#xD;
&#xD;
          -  Legal guardianship&#xD;
&#xD;
          -  Guardianship&#xD;
&#xD;
          -  Inability to give informed information to the patient&#xD;
&#xD;
          -  Pregnant women-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seitlinger</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <state>Lorraine</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>SEITLINGER Joseph</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>tyrosine kinase inhibitors</keyword>
  <keyword>Lung adenocarcinoma</keyword>
  <keyword>EGFR activating mutation</keyword>
  <keyword>KRAS Mutation-related tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

